CN108619214A - A kind of drug for treating tumour - Google Patents
A kind of drug for treating tumour Download PDFInfo
- Publication number
- CN108619214A CN108619214A CN201710153240.9A CN201710153240A CN108619214A CN 108619214 A CN108619214 A CN 108619214A CN 201710153240 A CN201710153240 A CN 201710153240A CN 108619214 A CN108619214 A CN 108619214A
- Authority
- CN
- China
- Prior art keywords
- drug
- tumour
- packets
- cancer
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 59
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 229940079593 drug Drugs 0.000 title claims abstract description 15
- 239000008280 blood Substances 0.000 claims abstract description 11
- 210000004369 blood Anatomy 0.000 claims abstract description 11
- 241000241413 Propolis Species 0.000 claims abstract description 10
- 229940069949 propolis Drugs 0.000 claims abstract description 10
- 241001165494 Rhodiola Species 0.000 claims abstract description 9
- 230000036651 mood Effects 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims abstract description 7
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims abstract description 6
- RVSTWRHIGKXTLG-UHFFFAOYSA-N Pangamic acid Natural products CC(C)N(C(C)C)C(N(C(C)C)C(C)C)C(=O)OCC(O)C(O)C(O)C(O)C(O)=O RVSTWRHIGKXTLG-UHFFFAOYSA-N 0.000 claims abstract description 6
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940055705 pangamic acid Drugs 0.000 claims abstract description 6
- ZQTHOIGMSJMBLM-BUJSFMDZSA-N pangamic acid Chemical compound CN(C)CC(=O)OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O ZQTHOIGMSJMBLM-BUJSFMDZSA-N 0.000 claims abstract description 6
- 108700024047 pangamic acid Proteins 0.000 claims abstract description 6
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 206010027476 Metastases Diseases 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims abstract description 5
- 239000011575 calcium Substances 0.000 claims abstract description 5
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 5
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract description 4
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 4
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 4
- 201000011510 cancer Diseases 0.000 claims description 39
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 6
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 6
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 229940074391 gallic acid Drugs 0.000 claims description 3
- 235000004515 gallic acid Nutrition 0.000 claims description 3
- 229930193195 schizandrin Natural products 0.000 claims description 3
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002158 endotoxin Substances 0.000 claims description 2
- 244000163122 Curcuma domestica Species 0.000 claims 1
- 235000003392 Curcuma domestica Nutrition 0.000 claims 1
- 244000061176 Nicotiana tabacum Species 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 235000003373 curcuma longa Nutrition 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 235000013976 turmeric Nutrition 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 25
- 241000208125 Nicotiana Species 0.000 abstract description 5
- 238000009792 diffusion process Methods 0.000 abstract description 5
- 231100000614 poison Toxicity 0.000 abstract description 4
- 239000002574 poison Substances 0.000 abstract description 4
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 230000000973 chemotherapeutic effect Effects 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 238000000746 purification Methods 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 9
- 230000036541 health Effects 0.000 description 8
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 5
- 235000005487 catechin Nutrition 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 4
- 241000976983 Anoxia Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000005907 cancer growth Effects 0.000 description 4
- 229950001002 cianidanol Drugs 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 241000256844 Apis mellifera Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010027940 Mood altered Diseases 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007681 cardiovascular toxicity Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108010050939 thrombocytin Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Animal Husbandry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to drugs, in particular it relates to a kind of drug for treating tumour.The curing oncoma drug of the present invention purifies the blood poison for means, rather than as traditional chemotherapeutic treats tumour to kill tumour cell as means to improve mood, confidence and purification blood.This drug improves mood, the ingredient of confidence has tobacco acid, psilocybin, rhodiola root extract, and the ingredient for purifying blood has lipoic acid, propolis and pangamic acid calcium.This drug solve the problems, such as traditional chemotherapeutic also and meanwhile kill healthy cell to accelerate patient that tumour diffusion and novel tumor medicine molecular targeted medicine be only consistent to target spot effectively and after one period the targeting medicine also make metastases, recur.
Description
Technical field
The present invention relates to a kind of drugs, in particular it relates to a kind of drug for treating cancer.
Background technology
Tumour be animals and humans organ-tissue cell it is external and it is interior under the long term of adverse factor produced by
It is a kind of using cell hyperproliferation as the neoformation of main feature, it can be divided into benign tumour and malignant tumour two major classes, cancer
It is then a kind of malignant tumour.
According to statistics, in global 7,000,000,000 populations, ten thousand people about more than 1000 suffer from cancer every year, because cancer died is up to hundreds of
Ten thousand.Have multiple countries and regions now and cancer is classified as first cause of the death, there are a countries and regions at least more than 20 to be classified as cancer
It is only second to the second largest cause of the death of cardiovascular and cerebrovascular disease.At the beginning of liberation, cancer occupied the 9th of China's cause of the death, to 90 years 20th century
In generation, just cancer once occupied the cause of the death first in China.The latest data of the publication of Chinese tumour Register 2 months 2016 shows, I
State is estimated to be 4,290,000 cancer new cases for 2015, because of cancer death toll more than 2,810,000.It can be seen that the prevention of cancer and controlling
Treatment has become the public health problem that China should pay much attention to.
The treatment of tumour mainly has operation, drug therapy, radiotherapy, cellular immunotherapy etc..Current drug therapy
Based on chemical synthetic drug treatment (referred to as " chemotherapy ").Facts proved that this for the purpose of killing tumour cell, rather than
Tumour cannot be cured for the therapy of the basic reason of tumour formation.On the contrary, it is because while killing tumour cell, also killing
Healthy cell makes patients immune system further destroy and patient tumors can be made to accelerate diffusion.(refer to September in 2014 30《It is long
Longevity health report》1st edition《Cancer also has natural enemy!Tackle the jinx of cancer:Immunocyte!》One text)
It as the saying goes:" pulling the grass up by its roots, cure the disease and ask source ".The root of disease formation is found, therapy is also just readily solved.
Scientific research proves that blood poison is excessively the chief culprit that tumour generates.When blood toxicity is excessive in vivo, if again without abundance
Nutrition supply oneself will manufacture enzyme and blood vessel, evolve into malignant tumour.It (refers to Fujian science tech publishing house to go out for 2013
Version, Wu Yongzhi write《Food is allowed to become your healthy good medicine with movement》One book page 33).
Separately there is scientific research to prove, anoxic can cause the excretion of vivotoxin to be obstructed.(Huaxia Press's publication is referred to, it is tall
Will perseverance writes《Science anti-aging, health arrive at the age of one hundred years old》One book page 28, version in 2012) therefore, anoxic can cause vivotoxin to be put aside,
It is damaged, makes a variation to make cell long-period be immersed in poison ring border, ultimately form tumour cell.It can be seen that anoxic is then facilitated
Tumour is formed.
Also scientific research proves, stress can also make body generate toxin, and generated toxin is bromatotoxin
Tens times of element.(refer to the publication in 2013 of Fujian science tech publishing house, Wu Yongzhi writes《Allow food with movement as your strong
Health good medicine》One book page 63) Pharmaceutical study institute of Monash University knubble biological scholar doctor Ai Likasilong
Results of animal show that stress is big, fast 6 times of cancer cell diffusion while interfering being smoothed out for treatment of cancer.(according to
On July 8th, 2016 Beijing《Life Times》3rd edition《Pressure is big, fast six times of cancer diffusion》One text) it can be seen that make to swell
Tumor energy rehabilitation, good mood are even more important.
In view of the foregoing, curing oncoma medicine should remove blood toxicity as first object to purify blood, and purify blood,
Mood must be improved again, improve confidence and eliminate body anoxia phenomenon.
The study found that tobacco is sour, psilocybin, rhodiola root can improve mood, inspires enthusiasm;Pangamic acid calcium can eliminate human body
Anoxia phenomenon;Lipoic acid, propolis can purify blood;Schizandrin, catechin, curcumin all have antitumor efficacy.But at present
It does not find the curing oncoma medicine for integrating these substances in the market, also has no the patent for the curing oncoma medicine for integrating these substances
Application, has then invented this drug.
The effect of this drug, ingredient included:
Tobacco acid:Also known as vitamin B7.The study found that most of tumor patients are suffering from depression.And depressive emotion meeting
The treatment difficulty of disease is set to increase, case fatality rate increases.Lack tobacco acid, is filled with unbounded confidence and wishes to life originally, strong people
It can become cowardly, dejected, anxiety etc..If giving subject supplements tobacco acid, after several hours, personality just becomes optimistic.
It (refers to China Textiles Press to publish for 2007, light rain is write《Food can change your mood》Page 52).
Psilocybin:A kind of alkaloids plant biochemistry element extracted from mushroom, can mitigate the anxiety of cancer patient
Mood.The studies have shown that of California, USA university takes the mood that 2 weeks cancer patients of psilocybin obviously suffer from spleen with anxiety
Symptom mitigates, and takes psilocybin and without side-effects.It (refers to Jiangsu science tech publishing house to publish for 2014, Sun Lihong writes
《What makes people rich what is said or talked about:Anticancer, you eat right》Page 87) alkaloid can improve the confidence and will of people.And anticancer, patient based on
Confidence is very crucial.Drug therapy is basis, and confidence, conviction are only the key of rehabilitation.If patient is in low spirits, burnt daily
Consider, loses the confidence to life, life, other such as drug therapies, kinesiatrics, diet care are not all known where to begin.Because bad
Mood will produce more toxin, these toxin are more much bigger to the harm of body than the toxin that diet, air are brought.(refer to 2016
Year June 10 mesh《Long-lived health report》Homepage《Each system toxin expelling study course of body》One text).
Rhodiola root:It is a kind of plant for being grown in highlands, has and promote endurance and antifatigue, inhibition growth of cancer cells
The effects that with diffusion, compressive resistance.After taking rhodiola root, thrombocytin concentration can be improved quickly.And depression is mostly due in vivo
Caused by thrombocytin deficiency.
Pangamic acid calcium:Also known as pangamic acid, it is a kind of water-soluble B vitamin.It is thin to in-vivo tissue that it can increase oxygen
Body anoxia phenomenon is eliminated in the transmission of born of the same parents.(refer to China Light Industry Press's publication, Cao Jingsong, Wang Xiaoqin write《Food nutrition
Hardening agent》Page 408) body anoxic is origin of hundreds of diseases.Most scholars think that human body anoxia can make body immune system lack of proper care,
The excretion of internal toxin is caused to be obstructed.Vivotoxin excretion is not gone out, and cell is damaged because being immersed in poison ring border, for a long time
In this way, impaired cell just generates variation, many diseases, including cancer, diabetes, cardiovascular disease etc. are then just generated.Moral
The famous physician of state, Nobel's medicine is pointed out with physiology prize winner Otto professor Wa Baige, when human tissue cell's oxygen
When content is less than the 65% of normal value, oxygen-starved tissue's cell is easy for canceration.(Huaxia Press's publication is referred to, Qiao Zhiheng writes《Section
Anti-aging is learned, health arrives at the age of one hundred years old》Page 28, version in 2012) cancer cell is anaerobics.Oxygen is more sufficient in body, and cancer cell is got over
It is difficult to survive;And normal cell, then on the contrary, oxygen is more, it is then more vibrant.Therefore, anticancer, it is necessary to eliminate body anoxic.
Lipoic acid:For a kind of biostearin antioxidant, blood, lymph and fat environment can be purified.And clean blood
Liquid energy makes Denucleation become healthy cell again.(publication of Fujian science tech publishing house is referred to, Wu Yongzhi writes《Allow food with fortune
It is dynamic to become your healthy good medicine》Page 83,63, version in 2013) make cancer cell " turning over a new leaf " --- it becomes healthy cell again, is cancer
It is extremely valuable in disease rehabilitation course.
Propolis:The resin that be honeybee acquire from the wound of the tender shoots of certain trees or bark, and it is mixed into honeybee mandibular gland
The opaque jelly of armaticity that secretion and beeswax are process, it is a kind of integration of drinking and medicinal herbs object, can improve human immunity
Function, anti-oxidant, antiviral, antifatigue, antibacterial, the activity for improving superoxide dismutase, moreover it is possible to purify blood, have notable
Anti-cancer function.The wild wise man of National Institutes of Health,Japan pine also doctor the study found that the diterpene product in propolis to swollen
Tumor has specific killing action.After cancer patient takes propolis, not only cancer cell can disappear, but also can mitigate chemotherapy, put
Toxic side effect caused by treating.China Agriculture Industitute Bee Research Center seas Liu Fu et al. pass through zoopery and practical clinical
It proves, propolis has good antitumaous effect.After certain cancers patient's large dosage takes propolis, growth of cancer cells and transfer obtain very
Good control, some patients even fully recover.(refer to Beijing " Golden Shield publishing house " publication in 2008, Guo Fangbin writes《Propolis
Magical magical effect》Page 42, China Medical Science Press 2011 publishes, Shao Xingjun et al. writes《The strength of propolis》15th,
Page 114) and to control cancer metastasis most important in treatment of cancer, because about 90% cancer mortality case is because cancer turns
Caused by shifting.(according to Beijing on July 12nd, 2016《Life Times》Page 3《New method is expected to block metastasis of cancer》One text).
Schizandrin:For a kind of antioxidant in Chinese medicine Schisandra chinensis, there is anti-oxidant, inhibition inflammatory reaction, inhibition
The effects that growth of cancer cells is with transfer, promotion tumor necrosis factor-alpha (TNF-α) cancer cell specific induction of apoptosis.(refer to Hunan science
Technology publishing house version in 2015, the works such as Jiang Shengrong《Illustrate health food pandect》Page 61).
Epigallocatechin gallic acid:For one kind of catechin.Catechin is water soluble antioxidant, can remove people
Internal free radical, it is pre- it is anti-aging, reduce cancer incidence;It can inhibit growth of cancer cells and transfer.In four kinds of catechins, table
The antioxidation of gallocatechol gallic acid is best.The antioxidation of catechin is 20 times of vitamin, vitamin E
50 times or more.(refer to the works such as the publication of Hunan science tech publishing house, Jiang Shengrong《Illustrate health food pandect》Page 283,57
Page, version in 2015).
Curcumin:A kind of biochemical element of oxidation resistant plant, the study found that it can allow just becomes health in the cell reversal of canceration
Cell.(according on June 4th, 2013《Long-lived health report》《Cancer, which is eaten, to be come》One text, Shanghai Univ. of Traditional Chinese Medicine professor He Yumin
Text).
Selenium:For a kind of trace mineral nutrient necessary to human body and a kind of natural powerful antioxidant, there is antioxygen
The effects that change, activated immune system, pre- anti-cancer and apoplexy, arthritis, Myocardial damage.In anticancer, mainly because it has side
Body aid endotoxin is discharged, and tumour can be made to cannot get the supply of nutrient to be suppressed the function of growth.Selenium can also make one mood change
It obtains more preferably, to beneficial to cancer rehabilitation.
Invention content
The purpose of the present invention is to provide a kind of drug for treating tumour.
The curing oncoma drug of the present invention solves traditional chemotherapeutic also while killing healthy cell to accelerate tumour thin
Cancer metastasis, recurrence and the high problem of price are spread and also made after novel one period of curing oncoma medicine molecular targeted agents to born of the same parents.
Implementation steps
1, prescription:(in terms of every packet 10g)
2, production operation:It is operated by the technological process of production of granule:
1. the preparation of rhodiola root extract
A, it extracts:500g rhodiola roots are weighed, after crushing, are extracted at twice under 10-12 times of 60-70% ethanol solution room temperature
It takes, each extraction time will be stirred continuously during 72h or more, extraction.It is discarded after finally filter residue is squeezed, acquired solution and two
Secondary extract liquor merges, and recycles ethyl alcohol through vacuum distillation, obtains extract liquor.
B, it settles:Using gelatin tannin sedimentation.Gelatin dosage is determined according to extract liquor first, then with 10% configured
Gelatin solution is added in extract liquor and is stirred continuously slowly, while appropriate diatomite is added, and settles 72h or more at normal temperatures.Through
Filter filters, the other particulate matters for removing gelatin tannate complex compound and its being adsorbed.
C, refined filtration:At a temperature of 20-30 DEG C, with 0.1-0.45 μm of filter membrane refined filtration, by vacuum concentration, evaporating temperature is
70 DEG C, vacuum degree 83KPa, it is 25% or so to be concentrated into solid content.
D, it is spray-dried:Rhodiola root extraction concentrate is spray-dried at 140-150 DEG C, obtains powdered rhodiola root extraction
Object.
2. Icing Sugar, citric acid, pangamic acid calcium, maltodextrin in prescription are weighed respectively by 1000 times of amounts, by their mixings
After appropriate purified water be added be sufficiently stirred, become paste material.
3. weighing remaining dispensing respectively by 1000 times of amounts to be added in above-mentioned creme, the mixing in blender.
4. being granulated, drying:To be uniformly mixed, the blank of dry and wet appropriateness is with grain granulation machine granulating and forming is waved, be allowed to be in
Graininess, and pass through the sieve of 6-8 mesh;Particle after molding is packed into charging tray, puts the temperature at 80-85 DEG C in dryer into
Middle baking, until being dried to moisture less than 5%.
5. screening, packaging:It is in irregular shape if granular size differs, need the sieve for using 6-8 mesh to be again sieved, to remove
Larger particles are removed, ensure that granular size is almost the same;Gained finished product is packed with aluminum foil sack, is sealed while hot, often packs 10g
Grain, then mounted box is got product.
Claims (1)
- It is described to improve mood and the tobacco acid content of confidence is 1. a kind of drug for treating tumour, is technically characterized in that 1000mg/ packets, psilocybin 30mg/ packets, rhodiola root extract 500mg/ packets;The lipoic acid content for purifying blood is 350mg/ Packet, propolis content are 1000mg/ packets, and pangamic acid calcium content is 400mg/ packets;The discharge of body aid endotoxin, the table for inhibiting tumour growth Gallocatechol gallic acid content is 300mg/ packets, and it is 1.5mg/ packets to prevent the schizandrin content of metastases, makes cancer The cell reversal of change becomes the turmeric cellulose content of healthy cell as 100mg/ packets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710153240.9A CN108619214A (en) | 2017-03-15 | 2017-03-15 | A kind of drug for treating tumour |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710153240.9A CN108619214A (en) | 2017-03-15 | 2017-03-15 | A kind of drug for treating tumour |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108619214A true CN108619214A (en) | 2018-10-09 |
Family
ID=63686256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710153240.9A Pending CN108619214A (en) | 2017-03-15 | 2017-03-15 | A kind of drug for treating tumour |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108619214A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| CN110959851A (en) * | 2019-11-18 | 2020-04-07 | 青海晨菲制药有限公司 | Application of agaricus bisporus gallic acid in functional food |
| CN114040767A (en) * | 2019-01-30 | 2022-02-11 | 钻石治疗公司 | Methods and compositions comprising 5HT receptor agonists for the treatment of psychological, cognitive, behavioral and/or mood disorders |
| US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| US11724985B2 (en) | 2020-05-19 | 2023-08-15 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12060328B2 (en) | 2022-03-04 | 2024-08-13 | Reset Pharmaceuticals, Inc. | Co-crystals or salts of psilocybin and methods of treatment therewith |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
-
2017
- 2017-03-15 CN CN201710153240.9A patent/CN108619214A/en active Pending
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12312375B2 (en) | 2017-10-09 | 2025-05-27 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US10947257B2 (en) | 2017-10-09 | 2021-03-16 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US10954259B1 (en) | 2017-10-09 | 2021-03-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11149044B2 (en) | 2017-10-09 | 2021-10-19 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11180517B2 (en) | 2017-10-09 | 2021-11-23 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11447510B2 (en) | 2017-10-09 | 2022-09-20 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11505564B2 (en) | 2017-10-09 | 2022-11-22 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11851451B2 (en) | 2017-10-09 | 2023-12-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11629159B2 (en) | 2017-10-09 | 2023-04-18 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US11939346B2 (en) | 2017-10-09 | 2024-03-26 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US10519175B2 (en) | 2017-10-09 | 2019-12-31 | Compass Pathways Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| CN114040767A (en) * | 2019-01-30 | 2022-02-11 | 钻石治疗公司 | Methods and compositions comprising 5HT receptor agonists for the treatment of psychological, cognitive, behavioral and/or mood disorders |
| US11738035B2 (en) | 2019-04-17 | 2023-08-29 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| US11564935B2 (en) | 2019-04-17 | 2023-01-31 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| US12447164B2 (en) | 2019-04-17 | 2025-10-21 | Compass Pathfinder Limited | Method for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| US12433904B2 (en) | 2019-04-17 | 2025-10-07 | Compass Pathfinder Limited | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| CN110959851A (en) * | 2019-11-18 | 2020-04-07 | 青海晨菲制药有限公司 | Application of agaricus bisporus gallic acid in functional food |
| US11958807B2 (en) | 2020-05-19 | 2024-04-16 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12291499B2 (en) | 2020-05-19 | 2025-05-06 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12110272B2 (en) | 2020-05-19 | 2024-10-08 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11834410B2 (en) | 2020-05-19 | 2023-12-05 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11724985B2 (en) | 2020-05-19 | 2023-08-15 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11746088B2 (en) | 2020-05-19 | 2023-09-05 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12060328B2 (en) | 2022-03-04 | 2024-08-13 | Reset Pharmaceuticals, Inc. | Co-crystals or salts of psilocybin and methods of treatment therewith |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108619214A (en) | A kind of drug for treating tumour | |
| Gopalakrishnan et al. | Moringa oleifera: A review on nutritive importance and its medicinal application | |
| Adkar et al. | Trapa bispinosa Roxb.: a review on nutritional and pharmacological aspects | |
| Mehwish et al. | Moringa oleifera–a functional food and its potential immunomodulatory effects | |
| KR20130039309A (en) | Garlic and yolk extract including functionality food composite for health | |
| KR101185699B1 (en) | Usage of the plant of genus ampelopsis and extracts thereof for manufacture of medicament and functional food | |
| CN105595224A (en) | Sea cucumber dunaliella salina glucosan selenium preparation and preparation process | |
| CN102697893B (en) | Application of black raspberry extract (BRBE) in preparation of drugs for treating gastric cancer | |
| CN101856384B (en) | Liver-protecting combination | |
| CN104222638A (en) | Functional feed for preventing and treating carp branchiomycosis and preparation method of functional feed | |
| CN103564495B (en) | Propolis and cordycepic hypha powder composition, as well as preparation and application thereof | |
| CN103262980A (en) | Selenium germanium chromium elements-enriched vitamin spirulina health-care rice flour | |
| CN101953857A (en) | Compound fermented Cordyceps powder (Paecilomyces bat moth Cs-4 bacteria powder) combination drug | |
| Wahyuni et al. | Bioactivity and Benefits of the Okra Plant (Abelmoschus Esculentus (L.) Moench.): Literature Review | |
| CN103232931A (en) | Vitamin, microelement and pine pee series health-care snake medicinal liquor for prolonging life | |
| Sarswat et al. | Effect of garlic on human health | |
| CN104758555B (en) | Treat the Chinese herbal medicine of seawater fish bacterial disease | |
| RU2452242C1 (en) | Biologically active food additive production method | |
| Kabbashi et al. | Extraction of bioactive compound from Acacia seyal gum, in vitro evaluation of antitumor activity of its crude extract against leukemia | |
| CN106591058A (en) | Propolis wine capable of enhancing immunity and preparation method thereof | |
| CN105147920B (en) | Medicine for treating tumor and preparation method thereof | |
| CN103892284A (en) | Selenium/germanium traditional Chinese medicine-enriched sweet potato rice noodles capable of prolonging life | |
| CN103393099A (en) | Natural strong antioxidant pine series extract capsule | |
| CN105918697B (en) | Feed additive, preparation method thereof and application thereof in aquatic animal feed | |
| CN1840011A (en) | Chinese medicine for treating prostate disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181009 |